Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Basics of building a private dermatology practice--a startup guide.

Dermatology online journal·2025
Same author

Scalp arteriovenous fistula with intracranial communication.

Cutis·2021
Same author

A cardiac computed tomography first strategy to evaluate chest pain in a rural setting: outcomes and cost implications.

Coronary artery disease·2019
Same author

Acroangiodermatitis of Mali and Stewart-Bluefarb syndrome.

Cutis·2019
Same author

Multinucleate cell angiohistiocytoma: Case report and literature review.

Journal of cutaneous pathology·2018
Same author

Home ultraviolet light therapy for psoriasis: why patients choose other options.

Dermatology online journal·2015

Related Experiment Video

Updated: Jun 24, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Keratolytics for psoriasis: are they necessary?

Richard McClain1, Brad A Yentzer, Steven R Feldman

  • 1Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Dermatology Online Journal
|March 14, 2009
PubMed
Summary

Keratolytic agents are commonly believed to improve topical medication penetration in psoriasis plaques. This study investigates whether this belief is supported by scientific evidence.

More Related Videos

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jun 24, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Area of Science:

  • Dermatology
  • Pharmacology
  • Biomedical Science

Background:

  • Psoriatic plaques are characterized by hyperkeratosis, which impedes topical drug delivery.
  • Keratolytic agents are often used to reduce plaque thickness and enhance medication penetration.
  • The necessity of keratolytic agents for effective topical therapy in psoriasis remains debated.

Purpose of the Study:

  • To critically evaluate the evidence supporting the use of keratolytic agents for enhancing topical medication penetration into psoriatic plaques.
  • To determine if keratolytic agents are essential for improving the efficacy of topical treatments for psoriasis.

Main Methods:

  • Systematic literature review of studies investigating keratolytic agents and topical drug penetration in psoriasis.
  • Analysis of in vitro and in vivo studies assessing the impact of keratolysis on drug permeation through psoriatic skin.
  • Evaluation of clinical trial data comparing topical treatments with and without keratolytic pre-treatment.

Main Results:

  • Limited direct evidence supports the routine requirement of keratolytic agents for enhancing topical medication penetration in psoriasis.
  • Some studies suggest alternative or adjunctive therapies may be equally or more effective.
  • The efficacy of keratolytic agents appears to be formulation-dependent and plaque-specific.

Conclusions:

  • The common belief that keratolytic agents are essential for topical medication penetration in psoriasis lacks robust scientific evidence.
  • Further research is needed to clarify the specific role and optimal use of keratolytic agents in psoriasis management.
  • Clinicians should consider evidence-based alternatives and individualized treatment approaches for topical psoriasis therapy.